HRs (95% CIs) for total mortality for various possible predictors for all subjects and by gender
| Variable | All | Men | Women |
|---|---|---|---|
| DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; TNF, tumour necrosis factor; VAS, visual analogue scale. | |||
| *Adjusted for age and sex. | |||
| HAQ (per 1 SD)* | 1.58 (1.37 to 1.82) | 1.68 (1.31 to 2.15) | 1.58 (1.32 to 1.89) |
| VAS patient global assessment (per 1 SD) * | 1.39 (1.20 to 1.60) | 1.33 (1.05 to 1.70) | 1.43 (1.19 to 1.72) |
| VAS pain (per SD)* | 1.30 (1.15 to 1.50) | 1.31 (1.04 to 1.64) | 1.31 (1.09 to 1.58) |
| Disease duration (per year)* | 1.01 (0.99 to 1.02) | 1.01 (0.99 to 1.02) | 1.00 (0.99 to 1.02) |
| Present prednisolone treatment (yes vs no)* | 1.07 (0.79 to 1.43) | 1.32 (0.80 to 2.20) | 0.95 (0.66 to 1.38) |
| Previous DMARD treatment (⩾3 vs <3)* | 1.02 (0.74 to 1,42) | 1.03 (0.90 to 1.19) | 1.01 (0.93 to 1.10) |
| Comorbidity* | 2.53 (1.82 to 3.52) | 1.75 (1.01 to 3.00) | 3.14 (2.08 to 4.74) |
| Anti-TNF exposed | |||
| Adjusted for age and sex | 0.86 (0.61 to 1.23) | 1.22 (0.68 to 2.19) | 0.72 (0.47 to 1.13) |
| Adjusted for age, sex and HAQ | 0.67 (0.45 to 0.95) | 0.96 (0.53 to 1.72) | 0.55 (0.35 to 0.86) |
| Adjusted for age, sex, HAQ and comorbidity | 0.65 (0.46 to 0.93) | 0.95 (0.53 to 1.71) | 0.52 (0.33 to 0.82) |